Post-marketing safety surveillance of voclosporin: an observational, pharmacovigilance study leveraging faers database study on the safety of voclosporin
BackgroundVoclosporin is a novel calcineurin inhibitor approved for the treatment of adult active lupus. Based on the US Food and Drug Administration Adverse Event Reporting System FDA Adverse Event Reporting System database, this study conducted a comprehensive evaluation of the safety characterist...
Saved in:
| Main Authors: | Zhi Wang, Yanhua Lang, Xuyan Liu, Yuxuan Wang, Leping Shao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1506760/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Voclosporin Induces Systemic Lipidomic Alterations: Implications for Lupus Nephritis Remission
by: Farsad Afshinnia, et al.
Published: (2024-08-01) -
The kidney injury biomarker profile of patients with lupus nephritis remains unchanged with the second-generation calcineurin inhibitor voclosporin
by: Biff F. Palmer, et al.
Published: (2025-03-01) -
Conducting a real-world study of Tumor Necrosis factor-alpha inhibitors-induced Systemic Lupus Erythematosus based on the FAERS database
by: Mengjiao He, et al.
Published: (2025-02-01) -
Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis
by: Hui Chen
Published: (2025-01-01) -
Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01)